Globus Medical, Inc. $GMED Stock Acquired by William Blair Investment Management LLC

William Blair Investment Management LLC raised its position in shares of Globus Medical, Inc. (NYSE:GMED – Free Report) by 12.6% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,447,365 shares of the medical device company’s stock after buying an additional 162,469 shares during the period. William Blair Investment Management LLC owned about 1.08% of Globus Medical worth $108,408,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Allworth Financial LP grew its stake in shares of Globus Medical by 3.5% in the third quarter. Allworth Financial LP now owns 12,797 shares of the medical device company’s stock worth $1,011,000 after purchasing an additional 436 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in Globus Medical by 335.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 143,614 shares of the medical device company’s stock valued at $10,758,000 after purchasing an additional 110,602 shares during the period. Maryland State Retirement & Pension System raised its position in Globus Medical by 14.7% during the 3rd quarter. Maryland State Retirement & Pension System now owns 6,743 shares of the medical device company’s stock valued at $505,000 after purchasing an additional 863 shares during the last quarter. Jacobi Capital Management LLC bought a new position in Globus Medical during the 3rd quarter valued at approximately $40,000. Finally, Illinois Municipal Retirement Fund raised its position in Globus Medical by 24.5% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 73,173 shares of the medical device company’s stock valued at $5,481,000 after purchasing an additional 14,412 shares during the last quarter. Institutional investors own 95.16% of the company’s stock.

Globus Medical Price Performance

GMED stock opened at $72.02 on Monday. Globus Medical, Inc. has a 1 year low of $70.39 and a 1 year high of $101.40. The company has a market cap of $9.54 billion, a P/E ratio of 17.69, a PEG ratio of 1.12 and a beta of 0.98. The firm has a 50-day moving average of $76.56 and a 200 day moving average of $82.71.

Globus Medical (NYSE:GMED – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The medical device company reported $1.23 EPS for the quarter, topping the consensus estimate of $1.20 by $0.03. The business had revenue of $763.72 million during the quarter, compared to analyst estimates of $792.39 million. Globus Medical had a net margin of 17.76% and a return on equity of 14.43%. Globus Medical’s quarterly revenue was down .7% compared to the same quarter last year. During the same period last year, the business posted $1.18 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, equities research analysts expect that Globus Medical, Inc. will post 4.98 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Needham & Company LLC dropped their price objective on Globus Medical from $117.00 to $100.00 and set a “buy” rating for the company in a report on Friday, November 6th. Truist Financial decreased their target price on Globus Medical from $100.00 to $90.00 and set a “buy” rating for the company in a report on Monday, November 9th. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a report on Friday, October 9th. Canaccord Genuity Group dropped their price target on Globus Medical from $115.00 to $105.00 and set a “buy” rating for the company in a research note on Friday, November 6th. Finally, Wells Fargo & Company lifted their price target on shares of Globus Medical from $99.00 to $100.00 and gave the company an “overweight” rating in a report on Friday, November 6th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $96.08.

Check Out Our Latest Stock Report on Globus Medical

Insider Transactions at Globus Medical

In other news, Director James R. Tobin sold 41,666 shares of the firm’s stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $75.16, for a total value of $3,131,616.56. Following the completion of the transaction, the director owned 15,000 shares in the company, valued at $1,127,400. This trade represents a 73.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ann Rhoads sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $85.00, for a total value of $425,000.00. Following the completion of the transaction, the director owned 35,384 shares of the company’s stock, valued at approximately $3,007,640. The trade was a 12.38% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 101,666 shares of company stock valued at $7,970,017. Corporate insiders own 18.38% of the company’s stock.

Globus Medical Company Profile

(Free Report)

Globus Medical is a medical device company focused on musculoskeletal care. Its products include implants and instruments used in spine surgery, as well as solutions for orthopedic trauma and other orthopedic procedures. The company also develops surgical technologies, including robotic navigation and imaging systems designed to support planning and guidance during procedures. Its portfolio expanded significantly in 2023 when Globus Medical completed its combination with NuVasive, a provider of spine care products and technologies.

Further Reading

Institutional Ownership by Quarter for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.